everolimus,lenvatinib,sunitinib,pembrolizumab,axitinib
merck,pfizer,eisai
['clear trial', 'kn-42', 'kn-426']
updated results from kn-426 &amp; clear trials: confirmed os significant benefit, different follow up times. but hazard ratios slightly worsening #asco23 
Oncólogo médico en @parctauli y Hospital de Barcelona. Vocal de la Junta Directiva de @sogug1. Wine lover. Life-enjoying!